{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:56:50Z","timestamp":1788955010203,"version":"build-2803163510"},"reference-count":84,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The standards of care for the initial treatment of patients with newly diagnosed multiple myeloma (NDMM) who are eligible for high-dose melphalan and autologous stem cell transplantation (HDM-ASCT) include highly active triplet and quadruplet regimens based on proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. These regimens are resulting in improved outcomes and increasingly high rates of minimal residual disease (MRD)-negative responses without HDM-ASCT as part of the upfront therapy. Furthermore, recent randomized studies have shown that, while transplant-based approaches as a frontline therapy result in significantly longer progression-free survival compared to non-transplant approaches, this has not translated into an overall survival benefit. Given these developments, and in the context of the treatment burden of undergoing HDM-ASCT, in addition to the acute toxicities and long-term sequelae of HDM, which are associated with the genotoxicity of melphalan, there is an increasing rationale for considering deferring upfront HDM-ASCT in select transplant-eligible patients and saving it as a treatment option for later salvage therapy. Here, we review the latest clinical trial data on upfront or deferred HDM-ASCT and on the activity of quadruplet induction regimens, including rates of MRD-negative responses, and summarize emerging treatment approaches in the upfront setting such as the use of MRD-directed therapy and alternatives to HDM-ASCT.<\/jats:p>","DOI":"10.3390\/cancers15245709","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T08:09:17Z","timestamp":1701763757000},"page":"5709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease\/Risk-Adapted Therapy"],"prefix":"10.3390","volume":"15","author":[{"given":"Clifton","family":"Mo","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, 450 Brookline Avenue, Dana 1B02, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Hartley-Brown","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, 450 Brookline Avenue, Dana 1B02, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, 450 Brookline Avenue, Dana 1B02, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, 450 Brookline Avenue, Dana 1B02, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer Statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"NIH National Cancer Institute Surveillance, Epidemiology, and End Results Program (2023, October 23). Cancer Stat Facts: Myeloma, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: A Report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for Multiple Myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple Myeloma","volume":"397","author":"Pawlyn","year":"2021","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric Assessment Predicts Survival and Toxicities in Elderly Myeloma Patients: An International Myeloma Working Group Report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A Simplified Frailty Scale Predicts Outcomes in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated in the First (Mm-020) Trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1247808","DOI":"10.3389\/fonc.2023.1247808","article-title":"Editorial: Risk Factors in Multiple Myeloma Identified before and During Treatment: Are We Ready to Personalize Treatment?","volume":"13","author":"Terragna","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bar, N., Firestone, R.S., and Usmani, S.Z. (2023). Aiming for the Cure in Myeloma: Putting Our Best Foot Forward. Blood Rev., 101116.","DOI":"10.1016\/j.blre.2023.101116"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting Clinical Trial Data in Multiple Myeloma: Translating Findings to the Real-World Setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-Term Follow-up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma","volume":"38","author":"Joseph","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"Nccn Guidelines(R) Insights: Multiple Myeloma, Version 3.2022","volume":"20","author":"Callander","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and Opportunities in the Treatment of Relapsed-Refractory Multiple Myeloma: Consensus Recommendations of the Nci Multiple Myeloma Steering Committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (Cartitude-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in Relapsed or Refractory Multiple Myeloma: Phase 2 Magnetismm-3 Trial Results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting Gprc5d Bispecific Antibody for Multiple Myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple Myeloma: Eha-Esmo Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up(Dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","article-title":"High-Dose Therapy with Single Autologous Transplantation Versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"13","author":"Koreth","year":"2007","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Ifm 2009 Trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with Cyclophosphamide and Dexamethasone or Lenalidomide and Dexamethasone Plus Autologous Transplantation or Carfilzomib Plus Lenalidomide and Dexamethasone, Followed by Maintenance with Carfilzomib Plus Lenalidomide or Lenalidomide Alone for Patients with Newly Diagnosed Multiple Myeloma (Forte): A Randomised, Open-Label, Phase 2 Trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous Haematopoietic Stem-Cell Transplantation Versus Bortezomib-Melphalan-Prednisone, with or without Bortezomib-Lenalidomide-Dexamethasone Consolidation Therapy, and Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (Emn02\/Ho95): A Multicentre, Randomised, Open-Label, Phase 3 Study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/S2352-3026(22)00350-7","article-title":"Upfront Autologous Haematopoietic Stem-Cell Transplantation Versus Carfilzomib-Cyclophosphamide-Dexamethasone Consolidation with Carfilzomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma in England and Wales (Cardamon): A Randomised, Phase 2, Non-Inferiority Trial","volume":"10","author":"Yong","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: The Manhattan Nonrandomized Clinical Trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, Thalidomide, and Dexamethasone with or without Daratumumab before and after Autologous Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (Cassiopeia): A Randomised, Open-Label, Phase 3 Study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone for Transplant-Eligible Newly Diagnosed Multiple Myeloma: The Griffin Trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","article-title":"The Mutagenic Impact of Melphalan in Multiple Myeloma","volume":"35","author":"Maura","year":"2021","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood.2022017094","article-title":"High-Dose Melphalan Treatment Significantly Increases Mutational Burden at Relapse in Multiple Myeloma","volume":"141","author":"Samur","year":"2023","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the Initiation of Multiple Myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of Acute Myeloid Leukemia and Myelodysplastic Syndrome after Autotransplants for Lymphomas and Plasma Cell Myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood-2022-159357","article-title":"Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide\/Dexamethasone with Lenalidomide\/Dexamethasone Induction, Mel140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma","volume":"140","author":"Straka","year":"2022","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.17410","article-title":"Guidelines on the Diagnosis, Investigation and Initial Treatment of Myeloma: A British Society for Haematology\/UK Myeloma Forum Guideline","volume":"193","author":"Sive","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"Astct Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transpl. Cell Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple Myeloma: 2022 Update on Diagnosis, Risk Stratification, and Management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_41","unstructured":"mSMART (2023, October 23). Treatment Guidelines: Multiple Myeloma. Available online: https:\/\/www.msmart.org\/mm-treatment-guidelines."},{"key":"ref_42","first-page":"564","article-title":"The Evolving Role of Transplantation in Multiple Myeloma: The Need for a Heterogeneous Approach to a Heterogeneous Disease","volume":"16","author":"Gandolfi","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3109\/10428194.2012.751528","article-title":"Early Versus Delayed Autologous Stem Cell Transplant in Patients Receiving Novel Therapies for Multiple Myeloma","volume":"54","author":"Dunavin","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.transproceed.2015.12.031","article-title":"Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years","volume":"48","author":"Remenyi","year":"2016","journal-title":"Transpl. Proc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1038\/s41409-021-01371-1","article-title":"Outcomes after Delayed and Second Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma","volume":"56","author":"Lemieux","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and Outcomes of Patients with Multiple Myeloma Receiving Salvage Therapy after Bcma-Directed Car T Therapy","volume":"141","author":"Nath","year":"2023","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-Analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/psp4.12345","article-title":"Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients with Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant","volume":"7","author":"Cho","year":"2018","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s00277-020-04378-8","article-title":"Gastrointestinal Toxicity of High-Dose Melphalan in Autologous Hematopoietic Stem Cell Transplantation: Identification of Risk Factors and a Benchmark for Experimental Therapies","volume":"100","author":"Gordillo","year":"2021","journal-title":"Ann. Hematol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous Transplantation and Maintenance Therapy in Multiple Myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy Plus Lenalidomide Versus Autologous Transplantation, Followed by Lenalidomide Plus Prednisone Versus Lenalidomide Maintenance, in Patients with Multiple Myeloma: A Randomised, Multicentre, Phase 3 Trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bmt.1705471","article-title":"Oral Mucositis in Myeloma Patients Undergoing Melphalan-Based Autologous Stem Cell Transplantation: Incidence, Risk Factors and a Severity Predictive Model","volume":"38","author":"Grazziutti","year":"2006","journal-title":"Bone Marrow Transpl."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","article-title":"Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma","volume":"24","author":"Chakraborty","year":"2018","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/10428194.2020.1719091","article-title":"Health-Related Quality of Life Results from the Ifm 2009 Trial: Treatment with Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma","volume":"61","author":"Roussel","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","article-title":"Integrative Analysis of the Genomic and Transcriptomic Landscape of Double-Refractory Multiple Myeloma","volume":"4","author":"Ziccheddu","year":"2020","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated Single Cell Seeding in Relapsed Multiple Myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41375-022-01597-y","article-title":"Clonal Evolution after Treatment Pressure in Multiple Myeloma: Heterogenous Genomic Aberrations and Transcriptomic Convergence","volume":"36","author":"Misund","year":"2022","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1182\/bloodadvances.2022009138","article-title":"Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A Cibmtr Analysis","volume":"7","author":"Ragon","year":"2023","journal-title":"Blood Adv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-022-00640-6","article-title":"Increased Mortality Risk in Multiple-Myeloma Patients with Subsequent Malignancies: A Population-Based Study in The Netherlands","volume":"12","author":"Brink","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2022-165646","article-title":"Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed\/Refractory Multiple Myeloma Patients Following Bcma-Directed Car-T Cell Therapy","volume":"140","author":"Thibaud","year":"2022","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1002\/cncr.32941","article-title":"Morbidity Burden in Survivors of Multiple Myeloma Who Underwent Autologous Transplantation: A Bone Marrow Transplantation Survivor Study","volume":"126","author":"Arora","year":"2020","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"388.e1","DOI":"10.1016\/j.jtct.2023.02.011","article-title":"Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma","volume":"29","author":"Chakraborty","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.21.01137","article-title":"What the Princess Bride Teaches Us About Outcomes in Multiple Myeloma","volume":"39","author":"Lonial","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2022-162741","article-title":"Multivariable Analyses of Prognostic Factors for Progression-Free Survival (Pfs) and Complete Response (Cr) with Lenalidomide, Bortezomib, and Dexamethasone (Rvd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (Asct) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (Ndmm) in the Determination Phase 3 Trial","volume":"140","author":"Hassoun","year":"2022","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.clml.2019.09.622","article-title":"Minimal Residual Disease Status as a Surrogate Endpoint for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-Analysis","volume":"20","author":"Ludwig","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A Large Meta-Analysis Establishes the Role of Mrd Negativity in Long-Term Survival Outcomes in Patients with Multiple Myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1182\/blood.2023020284","article-title":"Potential Future Direction of Measurable Residual Disease Evaluation in Multiple Myeloma","volume":"142","author":"Mohty","year":"2023","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/j.clml.2023.02.005","article-title":"Association of Minimal Residual Disease Negativity Rates with Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"23","author":"Ficek","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1038\/s41467-023-40966-8","article-title":"Immunophenotypic Correlates of Sustained Mrd Negativity in Patients with Multiple Myeloma","volume":"14","author":"Coffey","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Leypoldt, L.B., Tichy, D., Besemer, B., Hanel, M., Raab, M.S., Mann, C., Munder, M., Reinhardt, H.C., Nogai, A., and Gorner, M. (2023). Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J. Clin. Oncol., Online ahead of print.","DOI":"10.1200\/JCO.23.01696"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E230","DOI":"10.1002\/ajh.26995","article-title":"Predictive Role of Sustained Imaging Mrd Negativity Assessed by Diffusion-Weighted Whole-Body Mri in Multiple Myeloma","volume":"98","author":"Belotti","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-023-00794-x","article-title":"Integrated Analysis of Next Generation Sequencing Minimal Residual Disease (Mrd) and Pet Scan in Transplant Eligible Myeloma Patients","volume":"13","author":"Fonseca","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"102016","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective Evaluation of Minimal Residual Disease in the Phase Ii Forte Trial: A Head-to-Head Comparison between Multiparameter Flow Cytometry and Next-Generation Sequencing","volume":"60","author":"Oliva","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/bloodadvances.2020002037","article-title":"Clinical Value of Measurable Residual Disease Testing for Assessing Depth, Duration, and Direction of Response in Multiple Myeloma","volume":"4","author":"Wong","year":"2020","journal-title":"Blood Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1182\/blood-2022-156730","article-title":"Outcomes of Mrd-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-Krd) and Autologous Transplantation: Extended Follow up of the Master Trial","volume":"140","author":"Costa","year":"2022","journal-title":"Blood"},{"key":"ref_77","unstructured":"Sborov, D.W., Laubach, J., Kaufman, J.L., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L.J., Anderson, L.D., and Nathwani, N. (2022, January 25\u201327). Daratumumab (Dara) + Lenalidomide, Bortezomib, and Dexamethasone (Rvd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (Ndmm): Final Analysis of Griffin. Proceedings of the 19th International Myeloma Society (IMS) Annual Meeting (2022), Los Angeles, CA, USA. Abstract OAB-057."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone as Induction Therapy for Newly Diagnosed, Transplantation-Eligible Patients with Multiple Myeloma (Gmmg-Hd7): Part 1 of an Open-Label, Multicentre, Randomised, Active-Controlled, Phase 3 Trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2021-146040","article-title":"Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone as Extended Induction and Consolidation Followed by Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (Ndmm) Patients (Ifm 2018-01): A Phase Ii Study of the Intergroupe Francophone Du My\u00e9lome (Ifm)","volume":"138","author":"Perrot","year":"2021","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2022.40.16_suppl.8002","article-title":"Daratumumab Carfilzomib Lenalidomide and Dexamethasone as Induction Therapy in High-Risk, Transplant-Eligible Patients with Newly Diagnosed Myeloma: Results of the Phase 2 Study Ifm 2018-04","volume":"40","author":"Touzeau","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1182\/blood-2022-156309","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-Krd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the Gmmg-Concept Trial","volume":"140","author":"Weisel","year":"2022","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jamaoncol.2022.2424","article-title":"Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study","volume":"8","author":"Derman","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1182\/blood-2022-156328","article-title":"A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (the Skylark Trial)","volume":"140","author":"Mo","year":"2022","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2022-157021","article-title":"Dvrd Followed by Ciltacabtagene Autoleucel Versus Dvrd Followed by Asct in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (Emagine\/Cartitude-6)","volume":"140","author":"Boccadoro","year":"2022","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:33:31Z","timestamp":1760132011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/24\/5709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":84,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15245709"],"URL":"https:\/\/doi.org\/10.3390\/cancers15245709","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]}}}